Research progress and prospects of prostate cancer-specific near-infrared fluorescent probes

doi:10.3877/cma.j.issn.1674-3253.2024.01.002

Abstract

Lin Zhang, Bo Wu, Dongwen Wang. Research progress and prospects of prostate cancer-specific near-infrared fluorescent probes[J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(01): 6-11.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2024.01.002

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2024/V18/I01/6

Figures/Tables 1

References 41

[1]	Liu J, Dong L, Zhu Y, et al. Prostate cancer treatment - China's perspective [J]. Cancer Lett, 2022, 550: 215927.
[2]	Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020 [J]. Cancer Commun (Lond), 2021, 41(10): 1037-1048.
[3]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022 [J]. CA Cancer J Clin, 2022, 72(1): 7-33.
[4]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants [J]. Chin Med J (Engl), 2022, 135(5): 584-590.
[5]	Sekhoacha M, Riet K, Motloung P, et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches [J]. Molecules, 2022, 27(17): 5730.
[6]	Geczi T, Simonka Z, Lantos J, et al. Near-infrared fluorescence guided surgery: state of the evidence from a health technology assessment perspective [J]. Front Surg, 2022, 9: 919739.
[7]	He K, Li P, Zhang Z, et al. Intraoperative near-infrared fluorescence imaging can identify pelvic nerves in patients with cervical cancer in real time during radical hysterectomy [J]. Eur J Nucl Med Mol Imaging, 2022, 49(8): 2929-2937.
[8]	He K, Hong X, Chi C, et al. Efficacy of near-infrared fluorescence-guided hepatectomy for the detection of colorectal liver metastases: a randomized controlled trial [J]. J Am Coll Surg, 2022, 234(2): 130-137.
[9]	Krishnan G, van den Berg NS, Nishio N, et al. Fluorescent molecular imaging can improve intraoperative sentinel margin detection in oral squamous cell carcinoma [J]. J Nucl Med, 2022, 63(8): 1162-1168.
[10]	Zhang NN, Lu CY, Chen MJ, et al. Recent advances in near-infrared II imaging technology for biological detection [J]. J Nanobiotechnology, 2021, 19(1): 132.
[11]	Meng X, Pang X, Zhang K, et al. Recent advances in near-infrared-II fluorescence imaging for deep-tissue molecular analysis and cancer diagnosis [J]. Small, 2022, 18(31): e2202035.
[12]	Shinn J, Lee S, Lee HK, et al. Recent progress in development and applications of second near-infrared (NIR-II) nanoprobes [J]. Arch Pharm Res, 2021, 44(2): 165-181.
[13]	Zhu S, Tian R, Antaris AL, et al. Near-infrared-II molecular dyes for cancer imaging and surgery [J]. Adv Mater, 2019, 31(24): e1900321.
[14]	Su Y, Yu B, Wang S, et al. NIR-II bioimaging of small organic molecule [J]. Biomaterials, 2021, 271: 120717.
[15]	Shi X, Zhang Z, Zhang Z, et al. Near-infrared window II fluorescence image-guided surgery of high-grade gliomas prolongs the progression-free survival of Patients [J]. IEEE Trans Biomed Eng, 2022, 69(6): 1889-1900.
[16]	Hu Z, Fang C, Li B, et al. First-in-human liver-tumour surgery guided by multispectral fluorescence imaging in the visible and near-infrared-I/II windows [J]. Nat Biomed Eng, 2020, 4(3): 259-271.
[17]	Becker F, Offermann A, Roesch MC, et al. Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker [J]. Urol Oncol, 2022, 40(8): 380 e11- e18.
[18]	Becker F, Joerg V, Hupe MC, et al. Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer [J]. Int J Cancer, 2020, 146(2): 577-588.
[19]	Chistiakov DA, Myasoedova VA, Grechko AV, et al. New biomarkers for diagnosis and prognosis of localized prostate cancer [J]. Semin Cancer Biol, 2018, 52(Pt 1): 9-16.
[20]	van der Toom EE, Axelrod HD, de la Rosette JJ, et al. Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies [J]. Nat Rev Urol, 2019, 16(1): 7-22.
[21]	Dorff TB, FantI S, Farolfi A, et al. The evolving role of prostate-specific membrane antigen-based diagnostics and therapeutics in prostate cancer [J]. Am Soc Clin Oncol Educ Book, 2019, 39: 321-330.
[22]	Wang F, Li Z, Feng X, et al. Advances in PSMA-targeted therapy for prostate cancer [J]. Prostate Cancer Prostatic Dis, 2022, 25(1): 11-26.
[23]	van de WielE C, Sathekge M, de Spiegeleer B, et al. PSMA expression on neovasculature of solid tumors [J]. Histol Histopathol, 2020, 35(9): 919-27.
[24]	Kwon H, Lim H, Ha H, et al. Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from alpha-amino acid with (S)- or (R)-configuration at P1' region [J]. Bioorg Chem, 2020, 104: 104304.
[25]	Tykvart J, Schimer J, Barinkova J, et al. Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery [J]. Bioorg Med Chem, 2014, 22(15): 4099-4108.
[26]	Davis MI, Bennett MJ, Thomas LM, et al. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase [J]. Proc Natl Acad Sci U S A, 2005, 102(17): 5981-5986.
[27]	Barinka C, Rovenska M, Mlcochova P, et al. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II [J]. J Med Chem, 2007, 50(14): 3267-73.
[28]	Liu T, Liu C, Zhang Z, et al. 64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer [J]. Eur J Nucl Med Mol Imaging, 2021, 48(13): 4508-4516.
[29]	Lundmark F, Olanders G, Rinne SS, et al. Design, synthesis, and evaluation of linker-optimised PSMA-targeting radioligands [J]. Pharmaceutics, 2022, 14(5): 1098.
[30]	Plichta KA, Graves SA, Buatti JM. Prostate-specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer [J]. Int J Mol Sci, 2021, 22(22): 12095.
[31]	Sindhwani S, Syed AM, Ngai J, et al. The entry of nanoparticles into solid tumours [J]. Nat Mater, 2020, 19(5): 566-575.
[32]	O'connor JP, Aboagye EO, Adams JE, et al. Imaging biomarker roadmap for cancer studies [J]. Nat Rev Clin Oncol, 2017, 14(3): 169-186.
[33]	Zhang RR, Schroeder AB, Grudzinski JJ, et al. Beyond the margins: real-time detection of cancer using targeted fluorophores [J]. Nat Rev Clin Oncol, 2017, 14(6): 347-364.
[34]	Hiyama E. Fluorescence image-guided navigation surgery using indocyanine green for hepatoblastoma [J]. Children (Basel), 2021, 8(11): 1015.
[35]	Ito R, Kamiya M, Urano Y. Molecular probes for fluorescence image-guided cancer surgery [J]. Curr Opin Chem Biol, 2022, 67:102112.
[36]	Paraboschi I, Mantica G, Minoli DG, et al. Fluorescence-guided surgery and novel innovative technologies for improved visualization in pediatric urology [J]. Int J Environ Res Public Health, 2022, 19(18): 11194.
[37]	Manny TB, Patel M, Hemal AK. Fluorescence-enhanced robotic radical prostatectomy using real-time lymphangiography and tissue marking with percutaneous injection of unconjugated indocyanine green: the initial clinical experience in 50 patients [J]. Eur Urol, 2014, 65(6): 1162-1168.
[38]	Sucher R, Brunotte M, Seehofer D. Indocyanine green fluorescence staining in liver surgery[J]. Chirurg, 2020, 91(6): 466-473.
[39]	Muraleedharan S, Tripathy K. Indocyanine green (ICG) angiography [M]. StatPearls. Treasure Island (FL). 2022.
[40]	Egloff-juras C, Bezdetnaya L, Dolivet G, et al. NIR fluorescence-guided tumor surgery: new strategies for the use of indocyanine green [J]. Int J Nanomedicine, 2019, 14: 7823-7838.
[41]	Uijen MJM, Derks YHW, Merkx RIJ, et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports [J]. Eur J Nucl Med Mol Imaging, 2021, 48(13): 4350-4368.

成像荧光基团（分子量）	成像波长	化合物名称	受体亲和力(竞争者)	亲油性	注射剂量
Cy7(665g/mol)	λex=753 nm λem=775 nm	Cy7−1	ki=1.0±0.5 pM(NAAG)	LogP=3.39	1 nmol
		Cy7−2	ki=7.0±0.4 pM(NAAG)	LogP=2.19	1 nmol
		Cy7−3	ki=5.0±0.2 pM(NAAG)	LogP=3.18	1 nmol
IRDye800CW(983 g/mol)	λ ex=774 nm λem=789 nm	IRDye800CW-1	ki=70±5 pM(NAAG)	LogP=2.45	1 nmol
		IRDye800CW-2	ki=40±10 pM(NAAG)	LogP=1.25	1 nmol
		IRDye800CW-3	ki=20±5 pM(NAAG)	LogP=3.21	1 nmol
IRDye800RS(825 g/mol)	λ ex=774 nm λem=789 nm	IRDye800RS-1	ki=100±10 pM(NAAG)	LogP=5.01	1 nmol
		IRDye800RS-2	ki=200±50 pM(NAAG)	LogP=3.81	1 nmol
		IRDye800RS-3	ki=4±0.5 pM(NAAG)	LogP=5.76	1 nmol
ICG(714 g/mol)	λ ex=780 nm λem=800 nm	ICG-1	ki=700±10 pM(NAAG)	LogP=5.65	1 nmol
		ICG-2	ki=400±60 pM(NAAG)	LogP=4.45	1 nmol
		ICG-3	ki=200±5 pM(NAAG)	LogP=6.40	1 nmol
IRDye800CW(983 g/mol)	λ ex=774 nm λem=789 nm	IRDye800CW-SCE	-	LogP=0.94	10 nmol
		DUPA-IR-Dye800CW	kD=12 nM(2-PMPA)	LogP=0.62	10 nmol
		ZJ-MCC-dEdE-dEGK(IR-Dye800CW)G	-	LogP=−2.67	2～10 nmol
		EUKL-cRGDfK-IRDye800	-	LogP=−2.21	1 nmol
		PSMA-1-IRDye800	IC50=1.5±0.1 nM(EuC)	LogP=−2.14±0.17	1 nmol
ZW800−1(997g/mol)	λ ex=772 nm λem=788 nm	KUE-PEG4-ZW800+3C	-	LogP=1.39	10 nmol
S0456(983 g/mol)	λ ex=774 nm λem=789 nm	OTL78	kD=4.7 nM(EuK-FITC)	LogP=1.19	1，3，10，30，60，90 nmol
成像荧光基团（分子量）	肿瘤摄取(时间点，细胞系)	肾脏摄取(时间点、细胞系)	清除途径(时间、摄取、清除器官)
Cy7(665g/mol)	30 AU(24 h，PC3-PIP)	20AU(24 h，PC3-PIP)	肾脏(24 h，肾脏20 AU，肝脏10 AU)
	200 AU(24 h，PC3-PIP)	28AU(24 h，PC3-PIP)	肾脏(24 h，肾脏28 AU，肝脏10 AU)
	200 AU(24 h，PC3-PIP)	30AU(24 h，PC3-PIP)	肾脏(24 h，肾脏30 AU，肝脏10 AU)
IRDye800CW(983 g/mol)	500 AU(24 h，PC3-PIP)	3 000 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏3 000 AU，肝脏28 AU)
	2 200 AU(24 h，PC3-PIP)	4 000 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏4 000 AU，肝脏13 AU)
	3 200 AU(24 h，PC3-PIP)	1 100 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏1 100 AU，肝脏20 AU)
IRDye800RS(825 g/mol)	0.05 AU(24 h，PC3-PIP)	0.10 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏0.10 AU，肝脏0.03 AU)
	0.20 AU(24 h，PC3-PIP)	0.25 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏0.25 AU，肝脏0.03 AU)
	0.29 AU(24 h，PC3-PIP)	0.29 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏0.29 AU，肝脏0.01 AU)
ICG(714 g/mol)	0.05 AU(24 h，PC3-PIP)	0.05 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏0.05 AU，肝脏0.03 AU)
	0.08 AU(24 h，PC3-PIP)	0.10 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏0.10 AU，肝脏0.05 AU)
	0.29 AU(24 h，PC3-PIP)	0.22 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏0.22 AU，肝脏0.05 AU)
IRDye800CW(983 g/mol)	160 AU，140 AU(12 h，24 h，LNCaP)	-	-
	-	-	-
	-	-	-
	1.53 AU(24 h，PC3-PIP)	1.53 AU(24 h, PC3-PIP)	肾脏(24 h，肾脏1.53 AU，肝脏0.5 AU)
	7.12%ID(120=h，PC3-PIP)28，35，52，58，71，65，60，50，38，31，35，22，(分别在0.8，0.17，0.5，1，2，6，8，24，48，72，96和120 h(体内)	0.004 AU(120 h,PC3-PIP)	肾脏(120 h，肾脏0.004 AU，肝脏0.002 AU)
ZW800−1(997g/mol)	4 AU(4 h，LNCaP)	13 AU(4h,LNCaP)	肾脏(4 h，肾脏13个AU，肝脏2.4个AU)
S0456(983 g/mol)	7.5 AU，15 AU，17.5 AU，11 AU，15 AU，15 AU(2 h，22Rv1细胞，1，3，10，30，60，90 nmol)	1.3 AU，1.8 AU，4.1 AU，5.9 AU，4.2 AU，1.0 AU(2 h，22Rv1胞，1，3，10，30，60，90 nmol)	肾(2 h，肾脏4.1 AU，肝0AU，10 nmol)

成像荧光基团（分子量）	成像波长	化合物名称	受体亲和力(竞争者)	亲油性	注射剂量
Cy7(665g/mol)	λex=753 nm λem=775 nm	Cy7−1	ki=1.0±0.5 pM(NAAG)	LogP=3.39	1 nmol
		Cy7−2	ki=7.0±0.4 pM(NAAG)	LogP=2.19	1 nmol
		Cy7−3	ki=5.0±0.2 pM(NAAG)	LogP=3.18	1 nmol
IRDye800CW(983 g/mol)	λ ex=774 nm λem=789 nm	IRDye800CW-1	ki=70±5 pM(NAAG)	LogP=2.45	1 nmol
		IRDye800CW-2	ki=40±10 pM(NAAG)	LogP=1.25	1 nmol
		IRDye800CW-3	ki=20±5 pM(NAAG)	LogP=3.21	1 nmol
IRDye800RS(825 g/mol)	λ ex=774 nm λem=789 nm	IRDye800RS-1	ki=100±10 pM(NAAG)	LogP=5.01	1 nmol
		IRDye800RS-2	ki=200±50 pM(NAAG)	LogP=3.81	1 nmol
		IRDye800RS-3	ki=4±0.5 pM(NAAG)	LogP=5.76	1 nmol
ICG(714 g/mol)	λ ex=780 nm λem=800 nm	ICG-1	ki=700±10 pM(NAAG)	LogP=5.65	1 nmol
		ICG-2	ki=400±60 pM(NAAG)	LogP=4.45	1 nmol
		ICG-3	ki=200±5 pM(NAAG)	LogP=6.40	1 nmol
IRDye800CW(983 g/mol)	λ ex=774 nm λem=789 nm	IRDye800CW-SCE	-	LogP=0.94	10 nmol
		DUPA-IR-Dye800CW	kD=12 nM(2-PMPA)	LogP=0.62	10 nmol
		ZJ-MCC-dEdE-dEGK(IR-Dye800CW)G	-	LogP=−2.67	2～10 nmol
		EUKL-cRGDfK-IRDye800	-	LogP=−2.21	1 nmol
		PSMA-1-IRDye800	IC50=1.5±0.1 nM(EuC)	LogP=−2.14±0.17	1 nmol
ZW800−1(997g/mol)	λ ex=772 nm λem=788 nm	KUE-PEG4-ZW800+3C	-	LogP=1.39	10 nmol
S0456(983 g/mol)	λ ex=774 nm λem=789 nm	OTL78	kD=4.7 nM(EuK-FITC)	LogP=1.19	1，3，10，30，60，90 nmol
成像荧光基团（分子量）	肿瘤摄取(时间点，细胞系)	肾脏摄取(时间点、细胞系)	清除途径(时间、摄取、清除器官)
Cy7(665g/mol)	30 AU(24 h，PC3-PIP)	20AU(24 h，PC3-PIP)	肾脏(24 h，肾脏20 AU，肝脏10 AU)
	200 AU(24 h，PC3-PIP)	28AU(24 h，PC3-PIP)	肾脏(24 h，肾脏28 AU，肝脏10 AU)
	200 AU(24 h，PC3-PIP)	30AU(24 h，PC3-PIP)	肾脏(24 h，肾脏30 AU，肝脏10 AU)
IRDye800CW(983 g/mol)	500 AU(24 h，PC3-PIP)	3 000 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏3 000 AU，肝脏28 AU)
	2 200 AU(24 h，PC3-PIP)	4 000 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏4 000 AU，肝脏13 AU)
	3 200 AU(24 h，PC3-PIP)	1 100 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏1 100 AU，肝脏20 AU)
IRDye800RS(825 g/mol)	0.05 AU(24 h，PC3-PIP)	0.10 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏0.10 AU，肝脏0.03 AU)
	0.20 AU(24 h，PC3-PIP)	0.25 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏0.25 AU，肝脏0.03 AU)
	0.29 AU(24 h，PC3-PIP)	0.29 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏0.29 AU，肝脏0.01 AU)
ICG(714 g/mol)	0.05 AU(24 h，PC3-PIP)	0.05 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏0.05 AU，肝脏0.03 AU)
	0.08 AU(24 h，PC3-PIP)	0.10 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏0.10 AU，肝脏0.05 AU)
	0.29 AU(24 h，PC3-PIP)	0.22 AU(24 h，PC3-PIP)	肾脏(24 h，肾脏0.22 AU，肝脏0.05 AU)
IRDye800CW(983 g/mol)	160 AU，140 AU(12 h，24 h，LNCaP)	-	-
	-	-	-
	-	-	-
	1.53 AU(24 h，PC3-PIP)	1.53 AU(24 h, PC3-PIP)	肾脏(24 h，肾脏1.53 AU，肝脏0.5 AU)
	7.12%ID(120=h，PC3-PIP)28，35，52，58，71，65，60，50，38，31，35，22，(分别在0.8，0.17，0.5，1，2，6，8，24，48，72，96和120 h(体内)	0.004 AU(120 h,PC3-PIP)	肾脏(120 h，肾脏0.004 AU，肝脏0.002 AU)
ZW800−1(997g/mol)	4 AU(4 h，LNCaP)	13 AU(4h,LNCaP)	肾脏(4 h，肾脏13个AU，肝脏2.4个AU)
S0456(983 g/mol)	7.5 AU，15 AU，17.5 AU，11 AU，15 AU，15 AU(2 h，22Rv1细胞，1，3，10，30，60，90 nmol)	1.3 AU，1.8 AU，4.1 AU，5.9 AU，4.2 AU，1.0 AU(2 h，22Rv1胞，1，3，10，30，60，90 nmol)	肾(2 h，肾脏4.1 AU，肝0AU，10 nmol)

Please choose a citation manager

Content to export

Research progress and prospects of prostate cancer-specific near-infrared fluorescent probes

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 1

References 41

Related Articles 0

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export

Research progress and prospects of prostate cancer-specific near-infrared fluorescent probes

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 1

References 41

Related Articles 0

Recommended Articles

Metrics

Comments